PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Carlos E. Bueso-Ramos, MD, PhD & Naval Daver, MD - Pathology Insights on Innovation in AML The Rapid Emergence of Precision Diagnostics & Novel Therapy Across the Spectrum of Care
Go online to PeerView.com/YCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium held in conjunction with the 2019 ASCP Annual Meeting in Phoenix, Arizona, pathology and hematology-oncology experts offer guidance on how to differentiate high-risk AML subtypes at diagnosis, determine useful prognostic features, and use the results of diagnostic testing to help guide the integration of newly validated treatment options into care. The expert panel also discusses the nuances of multidisciplinary collaboration between pathologists and hematologist-oncologists, including practical issues related to defining and establishing management protocols for high-risk and molecularly defined AML subtypes. Upon completion of this activity, participants should be better able to: Identify the molecular and histopathologic features of various AML subtypes, including secondary AML, AML-MRC, and FLT3- or IDH-mutant AML, Recommend appropriate evidence-based molecular/pathology testing for patients with a likely diagnosis of AML, Safely integrate novel treatment regimens into the management of patients with secondary AML/AML-MRC, Develop safe and effective management plans for patients with AML whose disease exhibits FLT3 or IDH mutations